41
Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer
Condition(s):Breast CancerLast Updated:August 11, 2021Not yet recruiting
Fulvestrant: 433 Clinical Trials, Page 5 of 44
Hide Studies Not Open or Pending
42
Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer
Condition(s):Breast CancerLast Updated:March 13, 2012Completed
43
Efficacy and Safety of 500mg of Fulvestrant
Condition(s):Breast CancerLast Updated:June 21, 2022Active, not recruiting
44
Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
Condition(s):Breast CancerLast Updated:May 19, 2021Terminated
45
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
Condition(s):Adenocarcinoma of EndometriumLast Updated:July 8, 2022Recruiting
46
The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer
Condition(s):Metastatic Breast CancerLast Updated:February 26, 2014Unknown status
47
A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer
Condition(s):Breast Cancer; HR+/HER2-negative Breast Cancer; MetastasisLast Updated:June 18, 2018Unknown status
48
Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)
Condition(s):Malignant Neoplasm of Breast Stage IVLast Updated:June 1, 2016Completed
49
A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
Condition(s):Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast CancerLast Updated:June 28, 2022Terminated
50
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
Condition(s):Breast NeoplasmsLast Updated:December 14, 2018Terminated